Mitsubishi UFJ Asset Management Co., Ltd. - ULTRAGENYX PHARMACEUTICAL IN ownership

ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 219 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q3 2023. The put-call ratio across all filers is 0.74 and the average weighting 0.2%.

Quarter-by-quarter ownership
Mitsubishi UFJ Asset Management Co., Ltd. ownership history of ULTRAGENYX PHARMACEUTICAL IN
ValueSharesWeighting
Q3 2023$198,499
-21.6%
5,568
+1.4%
0.00%
-100.0%
Q2 2023$253,208
-19.2%
5,489
-29.8%
0.00%0.0%
Q1 2023$313,462
-6.3%
7,817
+6.4%
0.00%0.0%
Q4 2022$334,526
+52.8%
7,349
+39.0%
0.00%0.0%
Q3 2022$219,000
-30.5%
5,288
+0.2%
0.00%0.0%
Q2 2022$315,000
+11.3%
5,279
+35.6%
0.00%0.0%
Q1 2022$283,000
-8.4%
3,892
+6.1%
0.00%0.0%
Q4 2021$309,000
+24.6%
3,667
+33.6%
0.00%0.0%
Q3 2021$248,000
-5.3%
2,7450.0%0.00%0.0%
Q2 2021$262,000
-27.6%
2,745
-13.7%
0.00%
-50.0%
Q1 2021$362,000
+24.0%
3,180
+50.6%
0.00%0.0%
Q4 2020$292,000
+31.5%
2,112
-21.7%
0.00%0.0%
Q3 2020$222,000
+6.7%
2,698
+1.4%
0.00%0.0%
Q2 2020$208,0000.0%2,660
-43.1%
0.00%
-33.3%
Q1 2020$208,000
+26.1%
4,674
+21.8%
0.00%
+50.0%
Q4 2019$165,000
+52.8%
3,839
+51.7%
0.00%0.0%
Q3 2019$108,000
-16.3%
2,530
+24.8%
0.00%0.0%
Q2 2019$129,000
-19.4%
2,027
-12.0%
0.00%
-33.3%
Q1 2019$160,000
+107.8%
2,303
+19.7%
0.00%
+50.0%
Q4 2018$77,000
-38.9%
1,924
+16.6%
0.00%
-33.3%
Q3 2018$126,0001,6500.00%
Other shareholders
ULTRAGENYX PHARMACEUTICAL IN shareholders Q3 2023
NameSharesValueWeighting ↓
GREAT POINT PARTNERS LLC 727,426$25,932,7374.72%
RTW INVESTMENTS, LP 5,405,089$192,691,4234.07%
First Light Asset Management, LLC 1,125,032$40,107,3913.81%
CHI Advisors LLC 215,000$7,664,7503.04%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 250,052$8,914,3543.00%
SPHERA FUNDS MANAGEMENT LTD. 259,135$9,238,1631.68%
Rock Springs Capital Management LP 1,476,441$52,635,1221.41%
SUVRETTA CAPITAL MANAGEMENT, LLC 679,459$24,222,7131.31%
Privium Fund Management B.V. 115,241$4,108,3411.22%
SECTOR GAMMA AS 115,166$4,105,6681.05%
View complete list of ULTRAGENYX PHARMACEUTICAL IN shareholders